Ο κόσμος Maggioli


Οι ολοκληρωμένες δραστηριότητές μας υποστηρίζουν τη Δημόσια Διοίκηση, τους Ελεύθερους Επαγγελματίες και τις Εταιρείες στην απλοποίηση των διαδικασιών και στη βελτίωση των υπηρεσιών
 

Λύσεις και υπηρεσίες


Η τεχνολογία και η γνώση ήταν πάντα το πάθος μας, η δουλειά μας και ο τρόπος με τον οποίο καταφέραμε πάντα να ανταποκρινόμαστε στις απαιτήσεις μιας συνεχώς εξελισσόμενης αγοράς
 
Πίσω

AI / XAI / Data / Cloud

RadioVal

International Clinical Validation of Radiomics Artificial Intelligence for Breast Cancer Treatment Planning

Call: HORIZON-HLTH-2021-DISEASE-04-04

Ref: Grant Agreement No. 101057699

Διάρκεια: Sep 2022 – Aug 2026 (48 months)

Προϋπολογισμός: € 5.838.576,00

Χρηματοδότηση: € 5.838.576,00

Χρήματα: € 318.750,00

Ρόλος: System Integrator, Technology provider, WP3 Leader

Δικτυακός τόπος: www.radioval.eu

LinkedIn: https://www.linkedin.com/showcase/radioval-project/

Twitter: https://twitter.com/RadioVal_AI

περιγραφή

RadioVal is the first multi-centre, multi-continental and multi-faceted clinical validation of radiomics-driven estimation of NAC response in breast cancer. The project builds on the repositories, tools and results of five EU-funded projects from the AI for Health Imaging (AI4HI) Network, including a large multi-centre cancer imaging dataset on NAC treatment in breast cancer. To test applicability as well as transferability, the validation with take place in eight clinical centres from three high-income EU countries (Sweden, Austria, Spain), two emerging EU countries (Poland, Croatia), and three countries from South America (Argentina), North Africa (Egypt) and Eurasia (Turkey). 

RadioVal will develop a comprehensive and standardised methodological framework for multi-faceted radiomics evaluation based on the FUTURE-AI Guidelines, to assess Fairness, Universality, Traceability, Usability, Robustness and Explainability. Furthermore, the project will introduce new tools to enable transparent and continuous evaluation and monitoring of the radiomics tools over time. The RadioVal study will be implemented through a multi-stakeholder approach, taking into account clinical and healthcare needs, as well as socio-ethical and regulatory requirements from day one.

Εταίρος

  • Universitat de Barcelona (Spain)
  • Universiteit Maastricht (Netherlands)
  • Quibim (Greece)
  • Maggioli (Italy)
  • SHINE 2Europe (Portugal)
  • NHG (Finland)
  • Hospital Universitario de la Comunidad Valenciana (Spain)
  • Karolinska Institutet (Sweden)
  • Medical University of Gdansk (Poland)
  • Medical University of Zagreb (Croatia)
  • Medizinische Universitaet Wien (Austria)
  • Hacettepe Universitesi (Turkey)
  • Alexander Fleming SA (Argentina)
  • Ain Shams University Asu Faculty of Medecine (Egypt)
  • Eibir Gemeinnutzige Gmbh (Austria)